Payment overview · 2025
General Payments
$447.80
20 reported records · 7 companies
Healthcare provider profile · identity verified
Andrew D Bryant, D.O
Allopathic & Osteopathic Physicians|Family Medicine · MADISON, WV · NPI 1194018093
Verified facts
What the public records show
CMS Open Payments records show Andrew D Bryant, D.O received $447.80 in general payments during 2025 across 20 reported records.
Exact Sciences Corporation accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $157.20 | 35.1% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $147.55 | 33.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.41 | 14.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.52 | 5.7% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $19.38 | 4.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.75 | 3.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.99 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $447.80 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $157.20 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $133.49 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $94.40 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $80.34 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $46.78 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 151 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 72 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 689 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 551 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 528 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 528 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 459 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 444 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 407 | 77 |
| Omeprazole | Omeprazole | 380 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 374 | 83 |
| Lisinopril | Lisinopril | 330 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 324 | 78 |
| Furosemide | Furosemide | 308 | 72 |
| Metformin Hcl | Metformin Hcl | 301 | 55 |
| Famotidine | Famotidine | 274 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 258 | 60 |
| Trazodone Hcl | Trazodone Hcl | 249 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 232 | 48 |
| Alprazolam | Alprazolam | 218 | 28 |
| Tramadol Hcl | Tramadol Hcl | 209 | 40 |
| Potassium Chloride | Potassium Chloride | 207 | 40 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 201 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 199 | 51 |
| Montelukast Sodium | Montelukast Sodium | 199 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 42 |
| Losartan Potassium | Losartan Potassium | 177 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 172 | 30 |
| Lorazepam | Lorazepam | 171 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 33 |
| Jardiance | Empagliflozin | 151 | 27 |
| Sertraline Hcl | Sertraline Hcl | 142 | 33 |
| Clonazepam | Clonazepam | 140 | 22 |
| Carvedilol | Carvedilol | 134 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 132 | 23 |
| Ibuprofen | Ibuprofen | 130 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 129 | 27 |
| Prednisone | Prednisone | 125 | 69 |
| Ozempic | Semaglutide | 119 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 26 |
| Simvastatin | Simvastatin | 118 | 23 |
| Donepezil Hcl | Donepezil Hcl | 116 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 26 |
| Meloxicam | Meloxicam | 116 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 25 |
| Pregabalin | Pregabalin | 110 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 30 |
| Glipizide | Glipizide | 104 | 17 |
| Eliquis | Apixaban | 103 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 98 | 17 |
| Farxiga | Dapagliflozin Propanediol | 96 | 22 |
| Diazepam | Diazepam | 95 | 20 |
| Finasteride | Finasteride | 95 | 20 |
| Ezetimibe | Ezetimibe | 88 | 20 |
| Alendronate Sodium | Alendronate Sodium | 85 | 18 |
| Allopurinol | Allopurinol | 85 | 21 |
| Glimepiride | Glimepiride | 84 | 15 |
| Clonidine Hcl | Clonidine Hcl | 82 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 81 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 26 |
| Buspirone Hcl | Buspirone Hcl | 74 | 19 |
| Januvia | Sitagliptin Phosphate | 73 | 12 |
| Metformin Hcl Er | Metformin Hcl | 73 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 19 |
| Mounjaro | Tirzepatide | 71 | 11 |
| Novolog Flexpen | Insulin Aspart | 70 | 17 |
| Entresto | Sacubitril/Valsartan | 67 | 13 |
| Trulicity | Dulaglutide | 66 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 16 |
| Linzess | Linaclotide | 63 | 14 |
| Ketoconazole | Ketoconazole | 62 | 32 |
| Spironolactone | Spironolactone | 62 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | 11 |
| Propranolol Hcl | Propranolol Hcl | 59 | suppressed |
| Sucralfate | Sucralfate | 55 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 54 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Ranolazine Er | Ranolazine | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Cephalexin | Cephalexin | 45 | 33 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Celecoxib | Celecoxib | 43 | 12 |
| Atenolol | Atenolol | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 13 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 30 |
| Azithromycin | Azithromycin | 39 | 33 |
| Lidocaine | Lidocaine | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 11 |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Metronidazole | Metronidazole | 34 | 14 |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Sulindac | Sulindac | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Fentanyl | Fentanyl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 23 |
| Temazepam | Temazepam | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ibu | Ibuprofen | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 11 |
| Topiramate | Topiramate | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 17 |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Nystatin | Nystatin | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Etodolac | Etodolac | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Desloratadine | Desloratadine | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | 11 |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $447.80 · 20 records | Exact Sciences Corporation | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, SKYRIZI, TRELEGY ELLIPTA, TREMFYA, VRAYLAR | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error